Radiation and praG for advanced soft tissue sarcoma
Part of Cancer clinical trials.
This trial tests a new way of giving radiation therapy (called spatially fractionated radiotherapy) combined with a treatment strategy called PraG (pembrolizumab and granulocyte-macrophage colony-stimulating factor) for people with soft tissue sarcoma that cannot be removed or has spread. The goal is to see if the combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of soft tissue sarcoma (not GIST, bone cancer, or Ewing's sarcoma).
- Your sarcoma is locally advanced and cannot be removed, or it has come back or spread to other parts of the body.
- You have had at least 4 weeks since your last anti-cancer treatment, and any side effects from it have mostly gone away.
- You have at least one tumor that can be measured.
- Your overall health is good enough to do daily activities (ECOG score 0-2).
- Your blood counts, liver, kidney, and heart function meet the required levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a newer way of giving radiation (spatially fractionated) compared to standard radiation for people with large soft tissue sarcomas. It aims to see if the new method works better.
This trial tests a combination of radiation therapy and two drugs (anlotinib and penpulimab) given before surgery for soft tissue sarcoma. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial studies a high-dose, shortened course of proton beam radiation for people with soft tissue sarcoma that cannot be removed by surgery. It aims to improve tumor control while reducing side effects.
This trial is testing a new combination of four treatments (an experimental drug, two chemo-like drugs, and radiation) for advanced soft tissue sarcoma that hasn't responded to earlier treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial combines cryoablation (a freezing technique to destroy tumors) with camrelizumab (an immunotherapy drug that helps your immune system fight cancer) for patients with advanced soft tissue sarcoma that hasn't responded to standard treatments. The goal is to see if this combination works better than current options.
This trial tests a new approach for people with a rare type of cancer called retroperitoneal sarcoma, which grows in the back of the belly. It combines a short course of radiation and an immunotherapy drug before surgery, aiming to shrink the tumor and improve the chances of successful removal.
Hear when a new Soft Tissue Sarcoma (STS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.